Financial Performance - The company reported a total revenue of 1.5 billion RMB for the last fiscal year, representing a year-over-year growth of 15%[29]. - The company achieved a total operating revenue of CNY 2.704 billion in 2022, representing an increase of 8.83% compared to 2021[32]. - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, indicating a projected growth of 20%[29]. - The company achieved a net profit of 300 million RMB, reflecting a net profit margin of 20%[29]. - The net profit attributable to shareholders was CNY 88.01 million, a decrease of 7.58% from the previous year[32]. - The company reported a non-operating income of ¥24,626,661.74 in 2022, an increase of 47.1% compared to ¥16,745,362.17 in 2021[130]. - Total revenue for 2022 reached ¥2,704,144,046.05, representing an 8.83% increase from ¥2,484,828,437.08 in 2021[182]. Dividend and Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 0.5 RMB per 10 shares (including tax) based on a total of 1,618,715,253 shares[3]. - The company did not propose a cash dividend distribution plan despite positive profits available for distribution to shareholders[191]. - The cash dividend policy is compliant with the company's articles of association and shareholder resolutions, ensuring transparency and clarity in the dividend standards and ratios[198]. Research and Development - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[29]. - The company is actively developing new products and has submitted applications for consistency evaluations for several generic drugs[43]. - The R&D investment as a percentage of operating income was 5.36%, down from 6.63% in the previous year[59]. - The company has multiple ongoing R&D projects aimed at expanding its product pipeline, including cardiovascular and diabetes-related raw materials[58]. - The company has a strong focus on R&D for high-barrier specialty raw materials, with several projects in the validation or trial production stages[165]. - The company has established a national-level enterprise technology center and has completed 13 national projects and 35 provincial projects, holding 64 domestic invention patents and 4 PCT patents[171]. Market and Customer Base - The user base has expanded to 5 million active users, an increase of 25% compared to the previous year[29]. - Market expansion efforts include entering two new international markets, projected to increase overall market share by 10%[29]. - The company has a strong international customer base, maintaining long-term collaborations with major pharmaceutical companies such as Pfizer and Novartis, and its specialty raw materials are exported to multiple countries[173]. - The company’s sales revenue for the penem series increased by 60% year-on-year, with market share gradually rising[165]. - Domestic revenue reached approximately CNY 1.22 billion, accounting for 45.18% of total revenue, reflecting a 9.66% increase compared to the previous period[169]. - International revenue was approximately CNY 1.48 billion, representing 54.82% of total revenue, with an 8.15% growth compared to the previous period[169]. Compliance and Governance - The company emphasizes its commitment to ensuring the accuracy and completeness of its financial reports, with all board members present for the meeting[3]. - The company operates under the regulatory guidelines of the Shenzhen Stock Exchange for the chemical industry, ensuring compliance with disclosure requirements[3]. - The company's board of directors operates in compliance with legal and regulatory requirements, ensuring fair treatment of all shareholders[129]. - The company is committed to strict compliance with safety, environmental, and quality regulations to avoid potential risks[123]. Financial Health and Cash Flow - The cash flow from operating activities was CNY 116.09 million, up 13.41% from 2021[32]. - Total cash inflow from operating activities increased by 28.73% to ¥2,512,818,932.03 in 2022 from ¥1,951,965,146.22 in 2021[70]. - Net cash flow from operating activities rose by 13.41% to ¥116,092,038.77 in 2022 compared to ¥102,360,758.31 in 2021[70]. - The net increase in cash and cash equivalents was -¥550,973,287.70, a 56.80% decline compared to -¥351,394,028.30 in 2021[70]. - The proportion of cash and cash equivalents to total assets decreased from 22.79% at the beginning of 2022 to 17.76% at the end of 2022, a reduction of 5.03%[80]. Strategic Initiatives - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[29]. - The company aims to optimize its human resource management system to improve operational management levels and enhance employee motivation[122]. - The company is focused on cost reduction and efficiency improvement to enhance profitability and sustainable development[122]. - The company has established a biochemistry platform for enzyme discovery and fermentation, integrating discovery, development, and commercial production capabilities[179]. Production and Capacity - The company has a current API production capacity of over 1,200 tons, with an additional 970 tons under construction, and an intermediate production capacity of over 2,800 tons, with 3,200 tons also under construction[103]. - The company has completed the installation of equipment for its sterile powder injection production line, with a designed capacity of 50 million units[103]. - The company has expanded its CDMO project management efficiency, engaging in over 30 CDMO customer projects and entering commercial order phases for several projects expected to grow significantly in 2023[179]. - The company has developed a flexible production platform and completed 30 projects in small and pilot tests during the reporting period, focusing on new product development and CMO/CDMO project advancement[181]. Environmental and Social Responsibility - The company has made significant investments in environmental protection facilities, including a solid waste incineration capacity of 45,000 tons per year, enhancing its waste treatment capabilities[176]. - The company has received multiple environmental impact assessment approvals for various projects, indicating ongoing expansion and compliance with regulations[170].

Financial Performance - The company's operating revenue for the current period is ¥634,047,833.60, a decrease of 21.19% compared to the same period last year[20]. - Total operating revenue for the current period is $634.05 million, down 21.14% from $804.53 million in the previous period[33]. - Net profit attributable to shareholders for the current period is ¥42,101,946.61, down 51.62% year-over-year[20]. - Net profit for the current period is $41.85 million, a decrease of 51.66% compared to $86.55 million in the previous period[34]. - Basic and diluted earnings per share are both ¥0.02, down 60.00% from ¥0.05 in the previous year[20]. - The net profit after deducting non-recurring gains and losses is -¥3,289,938.74, representing a decline of 104.29% compared to the previous year[20]. Cash Flow - Net cash flow from operating activities was CNY 159,451,304.75, a slight increase from CNY 149,627,750.29, reflecting a growth of approximately 5.5%[14]. - Cash flow from financing activities generated a net inflow of CNY 603,707,509.29, compared to a net outflow of CNY -4,572,083.35 in the previous period[15]. - The company reported a net cash inflow from investing activities of CNY 81,685,962.84, a significant recovery from a net outflow of CNY -118,848,272.85 in the previous period[14]. - Net cash flow from investing activities improved by 168.73% to 81,685,962.84 from -118,848,272.85 mainly due to the recovery of investments and dividends[46]. - Net cash flow from financing activities increased significantly by 13,304.21% to 603,707,509.29 from -4,572,083.35 due to increased bank borrowings[46]. Assets and Liabilities - Total liabilities increased to CNY 2,912,033,729.61, up from CNY 2,288,184,973.02, representing a growth of approximately 27.2% year-over-year[10]. - The company’s total assets reached CNY 9,058,797,473.33, up from CNY 8,393,099,770.24, representing an increase of approximately 7.9%[10]. - Current assets totaled 4,027,776,667.20, up from 3,245,690,461.75, indicating a significant increase in liquidity[50]. - Cash and cash equivalents increased to 2,305,531,103.61 from 1,490,815,956.57, reflecting improved cash management[50]. - Total assets rose to 9,058,797,473.33 from 8,393,099,770.24, indicating growth in the company's asset base[50]. - Non-current assets decreased to 5,031,020,806.13 from 5,147,409,308.49, showing a reduction in long-term investments[50]. Shareholder Information - The company reported a total of 32,095 common shareholders at the end of the reporting period[27]. - The largest shareholder, Zhejiang Donggang Industrial Co., Ltd., holds 32.37% of the shares, totaling 523,982,587 shares[27]. - Shareholders' equity attributable to the parent company is ¥6,150,080,587.84, a slight increase of 0.24% compared to the previous year[20]. Operating Costs and Expenses - Total operating costs decreased to $642.13 million, a reduction of 9.25% from $708.00 million in the previous period[33]. - Financial expenses increased significantly to $24.96 million, up 547.97% from $3.85 million in the previous period, primarily due to exchange losses from the depreciation of the US dollar[44]. - Operating expenses increased by 96.56% to 245,032.99 from 124,663.16 primarily due to an increase in fixed asset scrapping[46]. - Income tax expenses decreased by 84.46% to 2,221,604.16 from 14,293,732.25 due to a reduction in total profit[46]. Foreign Exchange and Other Income - The company experienced significant foreign exchange losses due to large fluctuations in exchange rates during the reporting period[41]. - Non-operating income includes government subsidies of ¥3,564,265.41 and gains from the disposal of non-current assets of ¥8,248,695.14[21]. - Investment income rose to $20.09 million, an increase of 244.93% from $5.82 million in the previous period, mainly due to received dividends[44]. - The company reported a significant increase in asset disposal gains to $8.30 million, up 5023.79% from $162,040.17 in the previous period[44].

股票代码：002099 股票简称：海翔药业 公告编号：2023-021 浙江海翔药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 特此公告。 浙江海翔药业股份有限公司 董 事 会 二零二三年四月二十五日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日披露 了2022年年度报告。为了让广大投资者能进一步了解公司2022年度的经营情况， 公司将于 2023 年 5 月 5 日下午 15:00 至 17:00 在深圳证券交易所互动易平台举 办 2022 年度业绩说明会，与投资者进行沟通交流，听取投资者的意见和建议。 本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券交易所互动易 平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次业绩说明会。 公司出席本次业绩说明会的人员有：公司董事长王扬超、总经理许国睿、董 事会秘书王晓洋、财务总监朱勇、独立董事梁超。（如有特殊情况，参与人员会 有调整） 为充分尊重投资者、提升交流的针对性，现就公司 ...

Group 1: Company Overview - Zhejiang Haixiang Pharmaceutical Co., Ltd. is a global supplier of the penem industry chain, providing high-level intermediates and active pharmaceutical ingredients (APIs) [1] - The company is actively expanding strategic customer collaborations and optimizing customer structure [1] Group 2: Market and Financial Insights - The revenue scale and profitability of the penem series are expected to improve continuously, although there is uncertainty due to market price fluctuations [1] - In 2022, raw material price fluctuations had a significant impact, but the company has implemented various strategies to mitigate these effects, including long-term price locking with suppliers [1] Group 3: CMO/CDMO Developments - The company has seen unexpected growth in new project collaborations, particularly with European clients for Phase III clinical projects [2] - Future capital investments are expected to decrease compared to previous years, focusing on expanding CMO/CDMO capacity and enhancing the sterile system construction [2]

Group 1: Company Overview and Market Position - Zhejiang Haixiang Pharmaceutical Co., Ltd. is a global supplier of the full industrial chain for the Penam series, having established an independent Penam production facility in compliance with European and American drug regulations [1] - In the first three quarters of 2022, revenue from the Penam series increased by over 7% year-on-year, indicating significant growth potential as hospital admissions gradually recover [1] Group 2: Production Capacity and New Product Development - The company has completed the expansion of the entire Penam industrial chain within six months, with production capacity continuously increasing [1] - The production lines for active pharmaceutical ingredients (API) and sterile powder injections have been installed and are currently in the validation production phase [1] - The company is actively developing new products, including oral formulations and pediatric Penam, with over ten new products in the pipeline, some reaching pilot and validation production stages [2] Group 3: Research and Development Initiatives - The company is leveraging new technologies and processes to innovate existing products, reduce costs, and enhance competitiveness [2] - A new multi-functional CDMO workshop is planned to improve research and development efficiency, with the Shanghai research institute focusing on front-end process development and the Taizhou research institute on production scaling [2] Group 4: Strategic Growth and Investment - The company is committed to organic growth in the pharmaceutical sector while also considering external acquisition opportunities to strengthen its competitive advantage [2] - Suzhou Sihua, a 32.67% owned subsidiary, is performing well and represents a long-term investment for the company [2]

Group 1: Company Overview - The company is Zhejiang Haixiang Pharmaceutical Co., Ltd., with stock code 002099 [1] - The meeting took place on September 14, 2015, at Taizhou Liting Phoenix Mountain Villa [1] Group 2: Dye Products - Recent price trends for dye products show that the price of Reactive Blue has been stable with slight fluctuations [2] - The KN-R project has a designed capacity of 8,000 tons, which is currently fully operational, while the second phase is under construction and expected to be completed next year [2] - The company is a market leader in KN-R, holding a significant market share and being a drafter of national and industry standards [2] Group 3: Future Development Plans - The company plans to expand its product range by introducing over ten new products, including reactive and acid dyes, to reduce reliance on a single product for revenue [2] - New projects are backed by feasibility studies, ensuring that sales can absorb the increased production capacity [3] Group 4: Pharmaceutical Sector - The pharmaceutical segment has seen resource integration and refined management, resulting in a year-on-year gross margin increase of 2.7% [3] - Breakthroughs in formulation and custom processing businesses have significantly improved profitability, with Haikuo Biological expected to achieve a reduction in losses by the end of the year [3]

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|------------------------------|-------|--------------------------|--------------------| | | | | | 编号： 2015-001 | | | ■ | | 特定对象调研 □分析师会议 | | | | □ | | 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | | | 活动类别 | □ 现场参观 | | | | | | □ 其他 | | | | | 参与单位名称 | 光大证券胡银玉、榕树投资黄俊 | | | | | 及人员姓名 | | | | | | 时间 | 2015 年 5 月 6 日 | | | | | 地点 | 浙江省台州市椒江区解放南路 | 77-1 | | 号台州丽廷凤凰山庄 | | | 议事厅 | | | | | | 董事长：李维金 | | | | | 上市公司接待 | 财务总监：叶 ...